Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has signed and dated the Informed Consent after the study had been fully explained.~2. Patient is male or female, at least 20 years of age when the Informed Consent is obtained.~3. American Society for Anesthesiologists (ASA) I to III Class at the preoperative diagnosis.~4. New York Heart Association (NYHA) classification is I to III (Only patients who need classification of cardiac performance.)~5. Patient who requires sedation during the following elective surgery or procedure which require ≥30mins (expected time) without intubation under monitored sedation care.~   - Orthopedic, Otorhinologic, Oral surgeries, AV fistulas, Plastic, Excision of lesion, Breast biopsy, Catheter ablation, Vascular stents and AV shunt~6. Patient who requires local or regional anesthesia.~Exclusion Criteria:~1. Patient who underwent general anesthesia within 7 days, or who received other study drugs within 30 days from the date of consent.~2. Patient with \<92% SpO2 at the physical examination prior to the study drug administration, or ventilatory failure which requires intubation or Laryngeal Mask.~3. Patient with central nervous system pathology which may lead to increased intracranial pressure, uncontrolled seizures, psychiatric disorder which may be confused with the response to sedation treatment.~4. Patient who require neurosurgical or cerebrovascular catheter procedures or interventions.~5. Patient who require general anesthesia, epidural anesthesia or spinal anesthesia for surgery or procedure.~6. Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven days of scheduled surgery or procedure.~7. Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used in the study are contraindicated.~8. Patient diagnosed unstable angina or acute myocardiac infarction within 6 weeks from the date of consent.~9. Patient whose heart rate less than 50 bpm, systolic blood pressure less than 90 mm Hg by the physical examination prior to the study drug administration.~10. Patient has third degree heart block, unless the patient has a pacemaker.~11. Patient who has experienced an increase in alanine transaminase (ALT) and/or aspartate aminotransferase (AST) more than double the upper normal limit within 2 months of the date of consent, or who has a history of liver insufficiency.~12. Pregnant or lactating woman.~13. In the Investigator's or subinvestigator's opinion, patient has any symptom or factor, which might increase risk to the patient by conducting the study or preclude obtaining satisfactory study data.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): Loading infusion of Placebo over 10 minutes followed by maintenance infusion of Placebo
- DA-9501 0.5 mcg/kg group (Type: ACTIVE_COMPARATOR): Loading infusion of Dexmedetomidine 3.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
- DA-9501 1.0 mcg/kg group (Type: ACTIVE_COMPARATOR): Loading infusion of Dexmedetomidine 6.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete